Sarepta Therapeutics (FRA:AB3A) Payments of Debt: €-352 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AB3A Sarepta Therapeutics Inc FRA:AB3A
59 GF Score
Price €13.30
GF Value €111.08
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Payments of Debt?

Sarepta Therapeutics FRA:AB3A -4.45% 59 Payments of Debt is €-352 Mil as of Mar. 2026. GuruFocus rates FRA:AB3A with a GF Score™ of 59/100 and a GF Value™ of €111.08 (Possible Value Trap). The stock has 5 warning signs investors should review.

Sarepta Therapeutics's Payments of Debt for the three months ended in Mar. 2026 was €-216 Mil.

Sarepta Therapeutics's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was €-352 Mil.

Sarepta Therapeutics Payments of Debt Related Terms

Sarepta Therapeutics Payments of Debt Historical Data

* Premium members only.

The historical data trend for Sarepta Therapeutics's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Payments of Debt Chart

Sarepta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -777.13 0.00 -0.07 -138.85

Sarepta Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.97 -0.26 -105.60 -30.00 -216.25
FRA:AB3A
59GF Score
Sarepta Therapeutics Inc FRA:AB3A
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sarepta Therapeutics Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-352 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €-352 Mil mean?
Sarepta Therapeutics (FRA:AB3A) has a Payments of Debt of €-352 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Payments of Debt too high?
Sarepta Therapeutics' current Payments of Debt is €-352 Mil. Overall, Sarepta Therapeutics has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Payments of Debt compare to MPLT and ZYME?
Sarepta Therapeutics' Payments of Debt of €-352 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Payments of Debt is €-352 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (FRA:AB3A) is currently considered Possible Value Trap. The stock's GF Value™ is €111.08, compared to a current price of €13.30 — trading 88% below its estimated fair value. The current Payments of Debt is €-352 Mil. Sarepta Therapeutics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Sarepta Therapeutics (FRA:AB3A), the current Payments of Debt is €-352 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (FRA:AB3A) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of €13.30 is trading 88% below its estimated GF Value™ of €111.08. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:AB3A:

  • Payments of Debt: €-352 Mil
  • GF Value™: €111.08 vs. price of €13.30 (88% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the FRA:AB3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
59GF Score

Get the complete analysis for FRA:AB3A

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.30
Price
€111.08
GF Value